Conclusion
hypoglycemia, weight gain, T2DM
HYPOGLYCEMIA
Overall, the trial demonstrated improvement in glycemic control for fotagliptin monotherapy with 12 mg once daily in previously untreated T2DM patients uncontrolled with lifestyle intervention. Furthermore, fotagliptin treatment was not associated with greater risk of hypoglycemia episodes and weight gain, as compared with placebo and alogliptin. Thus, fotagliptin is a potential new approach for the treatment of T2DM patients who are inadequately controlled with diet and exercise intervention.